BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Investigation of maximum tolerated dose, safety, efficacy and pharmcokinetics of BI 811283 in
combination with cytarabine (LD-Ara-C) in previously untreated acute myeloid leukaemia (AML)
patients